Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage oncology company with Nasdaq-traded American depositary shares. Form 6-K reports furnish investor presentations, fact sheets, clinical updates for paxalisib, material-event disclosures, operating and financial results, and updates related to the company's oncology pipeline.
The filing record also covers capital structure and financing activity, including ADS sales agreements, registration-statement references, private placements, ordinary shares, pre-funded warrants, and placement-agent warrants. Governance disclosures include annual general meeting results, director and committee changes, and shareholder voting matters. Material-agreement filings describe licensing arrangements such as the SETDB1-targeted epigenetic platform, while risk and forward-looking disclosures address development-stage biotechnology, regulatory plans, clinical programs, and capital-market compliance.
Kazia Therapeutics Limited reports board changes, shareholder voting outcomes, and shares an updated corporate overview. Chairman Bryce Carmine will retire effective March 31, 2026, and the board will shrink from four to three directors, with Ebru Davidson joining the Audit, Risk and Governance Committee. The company states his resignation is not due to any disagreement over operations or policies. Shareholders re-elected director Steven Coffey, with 1,050,412,780 votes for and 3,637,588 against.
Kazia also furnishes a detailed investor presentation and fact sheet outlining its oncology pipeline. Lead asset paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, has been studied in more than 550 patients and is being advanced in glioblastoma, pediatric brain cancers, brain metastases, and triple negative breast cancer, where early Phase 1b data include one complete metabolic response and two partial responses. The company highlights cash and cash equivalents of about US$46 million, no debt, and an expected cash runway into 2029, as well as a preclinical PD-L1 protein degrader (NDL2) and VEGFR3 inhibitor EVT801.
Kazia Therapeutics Ltd ownership update: A Schedule 13G/A amendment reports that Jorey Chernett beneficially owned 1,588,129 American Depositary Shares as of the close of business on 02/19/2026, representing 13.90% of the class based on 11,426,899 ADS outstanding as of 03/12/2026.
The filing lists sole voting and dispositive power over those ADS and is signed on 03/31/2026.
Kazia Therapeutics Ltd reported that Alumni Capital LP, Alumni Capital GP LLC and Ashkan Mapar hold no American Depository Shares as of January 30, 2026. This Amendment No. 5 Schedule 13G/A functions as an exit filing, showing 0 shares and 0% ownership for each reporting person.
The filing lists the reporting persons' principal business address and confirms the General Partner and controlling person relationships; signatures are dated March 30, 2026.
Kazia Therapeutics Limited reported an unaudited half‑year loss of $12,552,490 for the six months ended 31 December 2025, wider than the prior period’s $10,453,811. Operating cash outflow was $9,540,623, but cash and cash equivalents rose sharply to $69,459,980 as of 31 December 2025 after substantial equity financing.
The company strengthened its balance sheet via private placements, including an approximately $50.0 million equity financing in December 2025 and issuance of pre‑funded warrants, and ended the period with net assets of $46,467,039. R&D focused on paxalisib in breast cancer and glioblastoma, alongside an in‑licensed PD‑L1 degrader program. The auditor’s review raised no independence issues.
Subsequently, Kazia entered a new at‑the‑market equity Sales Agreement with Leerink Partners LLC, allowing periodic sales of American Depositary Shares under an effective Form F‑3 shelf registration, and terminated its prior at‑the‑market program with Rodman & Renshaw LLC.
Kazia Therapeutics Limited filed a prospectus supplement registering 10,700,211 American Depositary Shares (representing 5,350,105,500 ordinary shares) to update the Prospectus dated December 23, 2025.
The supplement incorporates a Form 6-K that attaches the Company’s half‑year report for the six months ended 31 December 2025, reporting a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980. The supplement notes the ADSs trade on Nasdaq under the symbol KZIA and references private placement activity, including a December PIPE with reported net proceeds of US$46,509,833.
Kazia Therapeutics Limited is registering 266,666 American Depositary Shares representing 133,333,000 ordinary shares.
This prospectus supplement (to the December 22, 2025 prospectus) incorporates a Form 6-K furnished on March 19, 2026 and discloses the company’s half-year results for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as of 31 December 2025. The report also describes two private placements during the period, including a December 2025 placement with net proceeds of approximately $46.5M and an earlier placement of approximately $2.0M. The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price on March 18, 2026 was $7.51 per ADS.
Kazia Therapeutics Limited filed a prospectus supplement registering 232,956 American Depositary Shares, representing 116,478,000 ordinary shares, as set out in a prospectus supplement dated March 19, 2026.
The half‑year report for the six months ended 31 December 2025 shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980. Directors state the financial statements are prepared on a going concern basis. The company completed a private placement in December 2025 with expected net proceeds of $46.5 million to support clinical programs including paxalisib.
Registration covers 95,110 American Depositary Shares representing 47,555,000 ordinary shares, as set forth in a prospectus supplement to the Form F-1.
This supplement incorporates a Form 6-K dated March 19, 2026 attaching the company’s half‑year report for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as at 31 December 2025. The report discloses recent capital raises, including a private placement with net proceeds of approximately $46,509,833 and material issuances of ordinary shares and pre‑funded warrants closed in December 2025.
Kazia Therapeutics Limited reported an unaudited half-year loss of $12,552,490 for the six months ended 31 December 2025, wider than the prior period. Operating cash outflow was $9,540,623, reflecting ongoing pharmaceutical R&D spending.
Despite the loss, Kazia dramatically strengthened its balance sheet. Cash and cash equivalents rose to $69,459,980 at 31 December 2025, up from $4,344,691 at 30 June 2025, driven by equity financing and pre-funded warrant issuances totaling $75,321,410 of net cash inflow.
Net assets improved to $46,467,039, compared with a net liability position of $(8,301,449) at the previous year-end, helped by a large December private placement and ATM issuances that increased ordinary shares on issue to 5.67 billion. The company advanced its lead asset paxalisib in breast cancer and glioblastoma, and entered a new PD-L1 degrader collaboration, while auditors issued a clean review conclusion on the half-year accounts.